CDKN2B-AS1 and pancreatic neoplasm: Another study found that miR-181a targeting high-mobility group box 1 protein gene (HMGB1); Wang et al reported that ANRIL exacerbates the resistance of the chemotherapeutic drug gemcitabine in pancreatic cancer through inhibition of miR-181a thus activates HMGB1-induced autophagy [24].